Patents by Inventor Edward C. Scholtz

Edward C. Scholtz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20100255099
    Abstract: The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.
    Type: Application
    Filed: April 29, 2010
    Publication date: October 7, 2010
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Deog J. Kim, Young B. Lee, Chang H. Ahn, Edward C. Scholtz, Youngbuhm Huh
  • PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID
    Publication number: 20090270358
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.
    Type: Application
    Filed: October 24, 2008
    Publication date: October 29, 2009
    Applicant: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn, Edward C. Scholtz
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4983400
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: January 8, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4900755
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: February 13, 1990
    Assignee: Merck & Co.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4832957
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
    Type: Grant
    Filed: July 25, 1988
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines